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Abstract: Four new triterpenoid alkaloid derivatives, buxrugulines A–D (1–4), together with four known ones (5–8), were isolated 
from the leaves and stems of Buxus rugulosa. The structures of compounds 1–4 were elucidated by NMR and MS spectroscopic 
analysis. All compounds were assayed for their cytotoxicities against HL-60, SMMC-7721, A549, MCF-7, and SW480 cells lines. 
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Introduction 
Buxus rugulosa, belonging to the Buxus genus of the family 
Buxaceae, is a dwarf shrub growing in the rocky mountains in 
the northwest district of Yunnan Province. In previous phyto-
chemical investigations of the genus Buxus, more than 220 
triterpenoid alkaloid derivatives have been isolated1,2. This 
type of alkaloid showed interesting pharmacological activities 
such as anti-myocardial ischemia3,4, antibacterial activities5,6, 
and inhibition of cholinesterases7–9. In our previous studies 
from Buxus plants, new alkaloids with diverse structures and 
promising cytotoxic activities have been reported10,11. As part 
of this study, we have examined the stems and leaves of B. 
rugulosa, and consequently isolated four new triterpenoid 
alkaloid derivatives, buxrugulines A–D (1–4), along with four 
known ones, N20-acetoxy-cyclovirobuxin D (5)12, (+)-16α-
acetoxybuxabenzamidienine (6)13,14, moenjodaramine (7)9,15,16, 
irehine (8)17. Herein we report the isolation and structural elu-
cidation of the new compounds, as well as cytotoxic activities 
of the isolates from B. rugulosa. 
 
Results and Discussion 
A crude alkaloid fraction of B. rugulosa yielded eight 
triterpenoid alkaloid derivatives by repeated silica gel, amino 
silica gel, C-18 and Sephadex LH-20 chromatography. 
Buxruguline A (1) was obtained as white powder. Its 
molecular formula, C25H37NO, was established on the basis of 
HRESIMS analysis ([M + H]+, m/z 368.2944). The 1H NMR 
(Table 1) spectrum featured one N-methyl singlet at δH 2.47, 
four singlets at δH 0.80, 1.05, 1.17, and 1.26, corresponded to 
four tertiary methyl groups, and one doublet at δH 0.76 (6.5, H-
21). The 13C NMR spectrum exhibited 25 carbon signals 
containing six quaternary carbons (one carbonyl carbon at δC 
206.8 and two olefinic carbons at 146.1 and 146.3), eight 
methines (four olefinic carbons at δC 127.6, 127.7, 128.4, and 
 
Figure 1.  Structures of 1–8. 
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129.7), five methylenes, and six methyl groups. Comparison of 
the spectroscopic data of 1 and cyclobuxotriene13 revealed 
similarities except for the absence of a methyl on the nitrogen 
at C-20 and the presence of a double bond at C-6/7 in 1. This 
was supported by the HMBC correlations of H-5 (δH 2.73) 
with C-6 (δc 128.4) and of H-8 (δH 1.91) with C-7 (δc 127.6), 
C-9 (δc 146.1) (Figure 2). Therefore, 1 was elucidated as 
shown, and named buxruguline A. 
Buxruguline B (2) was obtained as colorless needles. The 
HRESIMS exhibited a quasi-molecular ion peak at m/z 
370.3105 ([M + H]+, calc. 370.3109), indicating the molecular 
formula C25H39NO. The 1H NMR spectrum featured three 
singlets for the three tertiary methyl groups at δH 0.85, 0.90, 
and 1.08, and the characteristic cyclopropyl methylene protons 
appeared as two doublets at δH − 0.04 and 0.50 (4.1). The 1H 
and 13C NMR spectrum of 2 displayed the presence of a 
terminal methylidene [δH 4.61, 4.85 (each, 1H, s); δH 153.3 (C), 
101.5 (CH2)]. All the data indicated that compound 2 was 
similar to buxpiine7, and the distinct difference between them 
was that a oxygenated methine (δC ≈ 72) of C-16 in buxpiine 
was replaced by a methylene (δC 34.2) in 2. This deduction 
was supported by HMBC correlations from H-21 (δH 1.08) to 
C-20 (δC 212.9), C-16 (δC 34.2) and from H-17 (δH 2.66) to C-
20, C-16 and C-13 (δC 42.7). H-5 is invariably α-oriented in 
this type alkaloid18,19, the ROESY correlation of H-3 (δH 2.85) 
with H-5 (δH 2.12) indicating an α-orientation of H-3 and β-
orientation of the amino functionality. So, the structure of 2 
was elucidated as shown in Figure 1. 
Buxruguline C (3) had the molecular formula C28H48N2O3, 
as determined by HRESIMS analysis ([M + H]+, m/z 
461.3749). The 1H NMR (CDCl3) spectrum of 3 showed the 
presence of three methyl singlets at δH 1.08, 0.60, and 0.92 for 
the H-18, H-31, and H-32, a doublet methyl at δH 1.01 (6.0, 
21-CH3), two N-methyl singlets at δH 2.45 and 2.88, together 
with characteristic protons due to one hydroxymethylene (δH 
2.93 and 3.25), and one oxygenated methine (δH 4.27). These 
spectral data were quite similar to those of 
dihydrocyclobaleabuxine20, except for the resonance of acetyl 
group [δH 1.92; δC 172.2 (C) and 22.3 (CH3)] attributable to 
the nitrogen at C-3. The relative configuration of 3 was 
elucidated by the ROESY experiment and comparision with 
other naturally occurring triterpenoid alkaloid possessing β-
configuration of the amino group at C-3, H-5α, and H-20β18,19. 
The ROESY correlations of H-5 (δH 1.84), and H-3 (δH 2.98) 
with H-30 (δH 2.93 and 3.25), and of H-20 (δH 2.97) with H-16 
(δH 4.27) indicated that H-30 was in α-orientation, while H-16 
was in β-orientation, respectively. Thus, the structure of 
buxruguline C was established as 3. 
The moleculr formula of buxruguline D (4) was assigned as 
C29H48N2O3 on the basis of the NMR data (Table 1) and 
HRESIMS. Comparison of the spectroscopic data of 4 and 3 
revealed similarities cycloartane-type triterpenoid skeleton. 
The notable difference was that a OH functionality at C-16 in 
3 was replaced by acetoxy group in 4, which confirmed by the 
downfielded H-16 (δH 4.11) proton signal and the HMBC 
correlation from H-16 to the O-acetyl carbonyl carbon at δC 
169.3 (C). Moreover 4 has one less hydroxyl function at C-30 
and one less methyl group on the nitrogen at C-3 than 3. 
Consequently, compound 4 was elucidated as shown and has 
been accorded the trivial name buxruguline D. 
Biologically, all compounds were tested for their cytotoxici-
ty against the HL-60, SMMC-7721, A549, MCF-7, and 
SW480 cells lines (Table 2). Compounds 6, 7 and 8 showed 
the better cytotoxic potential against A-549, and SW480 cell 
lines. Compounds 1–4 were noncytotoxic, with IC50 values > 
40 mol for all tested cell lines. 
 
Experimental Section 
General Experimental Procedures. Melting points were 
determined on a YU-HUA X-4 melting point apparatus. Opti-
cal rotations were obtained with a Horiba SEAP-300 polarime-
ter. Infrared spectra were recorded on a Shimadzu IR-450 in-
strument by using KBr pellets. NMR spectra were measured 
on a Bruker AV-400 and DRX-500 instrument (Bruker, Zűrich, 
Switzerland) with TMS as internal standard. HR-ESIMS data 
were recorded on a VG Auto Spec-3000 spectrometer. Silica 
gel (200300 mesh, Qingdao Marine Chemical, Inc), amino 
silica gel (75100 μm, Fuji Silysia Chemical LTD, Japan), C-
18 (2045 μm, Fuji Silysia Chemical, LTD, Japan), and Se-
phadex LH-20 (Pharmacia) were used for column chromatog-
raphy. 
 
Plant Material. Buxus rugulosa were collected at Lijiang 
(Yunnan), China, in February 2008. The sample was identified 
by Prof. Xi-Wen Li of the Kunming Institute of Botany, and a 
voucher specimen (KIB 20080210) has been deposited at the 
State Key Laboratory of Phytochemistry and Plant Resources 
in West China, Kunming Institute of Botany, Chinese Acade-
my of Sciences. 
 
Extraction and Isolation. The materials of B. rugulosa 
(75.0 kg) were extracted with 90% MeOH under reflux, the 
combined extracts were partitioned between EtOAc and 0.001 
mol/L HCl (pH ≈ 3.0). The aqueous layer was alkalinized to 
pH 10.0 with 2 mol/L NaOH followed by exhaustively extrac-
tion with CHCl3. The CHCl3-soluble fraction (180 g) was 
chromatographed on a silica gel column, eluted with CHCl3-
MeOH (1:0-0:1), to give four fractions (FA–FD). FB (45 g) 
was chromatographed on silica gel using petroleum ether (PE)-
EtOAc (8:1) as solvent and repeated Sephadex LH-20 eluted 
with MeOH to yield 7 (19 mg). After column chromatography 
on C-18 gel column chromatography by aqueous MeOH 
(60%-90%), amino silica gel column with PE-EtOAc (10:1) 
and CHCl3-MeOH (50:1), further separated by Sephadex LH-
20 eluted with MeOH, FC (14 g) to afford 1 (11 mg), 4 (4 mg), 
5 (6 mg), 7(28 mg), 8 (42 mg). FD (12 g) was chromato-
graphed on silica gel using CHCl3-MeOH (10:1, 5:1) as gradi-
 
Figure 2.  Key HMBC correlations for compound 1. 
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ent, and was further repeatedly separated on amino silica gel 
column chromatography, eluted with CHCl3-MeOH (20:1, 
10:1), to give 2 (6 mg), 3 (12 mg), 6 (76 mg). 
 
Buxruguline A (1)：white powder; mp 188–190°C; [α]24D + 
15.6 (c 1.04, CHCl3); UV (MeOH) λmax (log ε) 208 (3.78), 244 
(2.21) nm; IR (KBr) νmax: 1734 cm−1; 1H, 13C NMR data see 
Table 1; EIMS m/z: 367, HRESIMS m/z: 368.2944 [M + H]+ 
(calcd for C25H38NO [M + H]+, 368.2953). 
 
Buxruguline B (2)：colorless needle; mp 223–224゜C; 
[α]24D  + 18.4 (c 1.21, CHCl3); UV (MeOH) λmax (log ε) 205 
(3.59) nm; IR (KBr) νmax: 1735 cm−1; 1H, 13C NMR data see 
Table 1; ESIMS m/z: 370 [M + H]+; HRESIMS m/z 370.3105 
(calcd for C25H40NO [M + H]+, 370.3109). 
Table 1. 1H and 13C NMR Spectral Data of Buxrugulines A–D (1–4). 
 1a  2b 3c 4a  
position δC, type δH δC, type δH δC, type δH δC, type δH 
1a 29.7, CH2 2.04, overlap 31.0, CH2 1.82, overlap 32.4, CH2 1.56, overlap 31.6, CH2 1.65, overlap
1b  1.90, overlap  1.46, overlap 1.17, overlap  1.47, overlap
2a 46.6, CH2 2.34, m 25.7, CH2 1.73, overlap 27.0, CH2 1.55, overlap 25.6, CH2 1.33, overlap
2b  1.84, m  1.65, m  1.08, overlap
3 206.8, C  63.6, CH 2.85, m 51.3, CH 2.98, overlap 65.5, CH 3.75, m
4 44.3, C  153.3, C 44.0, C 42.2, C  
5 41.1, CH 2.73, d (3.5) 41.9, CH 2.12, m 40.2, CH 1.84, s 50.5, CH 2.16, s 
6a 128.4, CH 5.62, m 21.2, CH2 1.80, overlap 20.5, CH2 1.62, overlap 20.9, CH2 1.50, overlap
6b    1.18, overlap  0.76, overlap
7a 127.6, CH 5.42, m 26.2, CH2 1.58, overlap 25.4, CH2 1.22, overlap 28.4, CH2 1.75, m
7b    1.14, overlap 1.12, overlap  1.49, overlap
8 41.5, CH 1.91, overlap 42.4, CH 2.00, m 47.5, CH 1.35, overlap 47.3, CH 1.44, overlap
9 146.1, C  23.3, C 19.0, C 19.6, C  
10 146.3, C  32.0, C 25.5, C 25.8, C  
11a 127.7, CH 5.69, m 21.4, CH2 1.50, overlap 25.8, CH2 2.04, m 26.1, CH2 1.33, overlap
11b    1.16, overlap 1.04, overlap  1.08, overlap
12a 30.2, CH2 1.60, overlap 33.3, CH2 1.72, overlap 31.7, CH2 1.62, overlap 32.2, CH2 1.22, overlap
12b  1.50, m  1.55, overlap 1.44, overlap   
13 39.5, C  42.7, C 45.6, C 44.9, C  
14 41.5, C  46.0, C 47.7, C 48.0, C  
15a 24.8, CH2 2.04, overlap 22.4, CH2 1.52, overlap 45.5, CH2 1.82, overlap 45.0, CH2 1.38, overlap
15b  1.58, overlap  1.18, overlap 1.34, overlap   
16a 26.0, CH2 1.32, overlap 34.2, CH2 2.12, m 75.8, CH 4.27, m 78.5, CH 4.11, m 
16b    1.17, overlap   
17 47.5, CH 1.88, overlap 46.8, CH 2.66, m 56.1, CH 1.93, m 57.0, CH 1.88, m
18 19.7, CH3 0.80, s 18.3, CH3 0.85, s 18.9, CH3 1.08, s 19.0, CH3 0.97, s 
19 129.7, CH 6.51, s 22.0, CH2 0.50, d (4.1) 30.0, CH2 0.51, d (4.1) 30.2, CH2 0.53, d (4.1)
    − 0.04, d (4.1) 0.32, d (4.1)  0.35, d (4.1)
20 68.1, CH 2.09, m 212.9, C 64.1, CH 2.97, overlap 62.7, CH 2.71, m
21 15.3, CH3 0.76, d (6.5) 17.8, CH3 1.08, s 10.3, CH3 1.01, d (6.0) 9.8, CH3 0.91, d (6.5)
30a 20.5, CH3 1.26 (s) 101.5, CH2 4.85, s 63.7, CH2 3.25, m 11.4, CH3 0.76, s 
30b    4.61, s 2.93, m   
31 22.6, CH3 1.17, s  10.9, CH3 0.60, s 19.0, CH3 0.97, s 
32 25.8, CH3 1.05, s 11.5, CH3 0.90, s 20.3, CH3 0.92, s 21.1, CH3 1.15, s 
3-NCH3   34.5, CH3 2.50, s 35.3, CH3 2.45, s  2.30, s 
20-NCH3 35.3, CH3 2.47, s  30.5, CH3 2.88, s   
NCOCH3    172.2, C 171.4, C  
NCOCH3    22.3, CH3 1.92, s 21.0, CH3 2.09, s 
OCOCH3    169.3, C  
OCOCH3    23.6, CH3 1.96, s 
a1H and 13C NMR spectra were acquired at 500 (CDCl3) and 125 MHz (CDCl3), respectively. b1H and 13C NMR spectra were ac-
quired at 400 (CDCl3) and 100 MHz (CDCl3), respectively. c1H and 13C NMR spectra were acquired at 400 [CDCl3:MeOD (1:1)] 
and 100 MHz [CDCl3:MeOD (1:1)], respectively. 
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Buxruguline C (3)：colorless needle; [α]24D  + 8.8 (c 0.89, 
CHCl3); UV (MeOH) λmax (log ε ) 205 (3.53) nm; IR (KBr) νmax: 1698 cm−1; 1H, 13C NMR data see Table 1; ESIMS m/z 
461 [M + H]+; HRESIMS m/z 461.3749 (calcd for C28H49N2O3 
[M + H]+, 461.3743). 
 
Buxruguline D (4)：white powder; [α]24D  + 17.5 (c 0.72, 
CHCl3); UV (MeOH) λmax (log ε ) 203 (3.67) nm; IR (KBr) νmax: 1696 cm−1; 1H, 13C NMR data see Table 1; EIMS m/z 472 
[M + H]+; HRESIMS m/z 473.7114 (calcd for C29H49N2O3 [M 
+ H]+, 473.7109). 
 
Cell Culture and Cytotoxicity Assay. A panel of human 
tumor cell lines was used: promyelocytic leukemia HL-60, 
hepatocellular carcinoma SMMC-7721, alveolar basal 
epithelial carcinoma A549, breast adenocarcinoma MCF-7, 
and colon cancer SW480. The cells lines were obtained from 
the Shanghai cell bank of China. All the cells were cultured in 
RPMI-1640 or DMEM medium (Hyclone, USA), 
supplemented with 10% fetal bovine serum (Hyclone, USA) at 
37°C in a humidified atmosphere with 5% CO2. 
Cell viability was assessed by conducting colorimetric 
measurements of the amount of insoluble formazan formed in 
the living cells with the MTT (MTT, sigma, USA) method 
described before21, and using cisplatin (DDP, sigma, USA) as 
control. Cell growth inhibition curve was graphed and the IC50 
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Table 2. Cytotoxicity data of compounds 1–8 with IC50 values (μM). 
No. HL-60 SMMC-7721 A-549 MCF-7 SW480 
1 > 40 > 40 > 40 > 40 > 40 
2 > 40 > 40 > 40 > 40 > 40 
3 > 40 > 40 > 40 > 40 > 40 
4 > 40 > 40 > 40 > 40 > 40 
5 27.18 > 40 > 40 27.03 > 40 
6 15.23 28.99 19.39 14.39 14.69 
7 17.32 > 40 19.70 > 40 14.25 
8 21.35 > 40 23.52 > 40 17.18 
cisplatin 
(MW300) 
1.00 17.05  26.75 14.97 16.88 
